A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat

OBJECTIVE: We report the results of pharmacogenomics-based antidepressant treatment (PGXt) results in treating treatment-resistant major depressive disorder (TRD) patients in real practice. METHODS: Nine patients were prescribed Neuropharmagen(Ⓡ) for selection of antidepressants for individual patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Kyung Ho, Bahk, Won-Myong, Lee, Soo-Jung, Serretti, Alessandro, Pae, Chi-Un
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean College of Neuropsychopharmacology 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851455/
https://www.ncbi.nlm.nih.gov/pubmed/33508800
http://dx.doi.org/10.9758/cpn.2021.19.1.160
Descripción
Sumario:OBJECTIVE: We report the results of pharmacogenomics-based antidepressant treatment (PGXt) results in treating treatment-resistant major depressive disorder (TRD) patients in real practice. METHODS: Nine patients were prescribed Neuropharmagen(Ⓡ) for selection of antidepressants for individual patient and their clinical outcomes were followed. RESULTS: After treatment by PGXt results from current antidepressants, substantial reduction of depressive symptoms was observed at some point and maintained during observation period in six patients. CONCLUSION: Our case series potentially shows the clinical utility and benefit of PGXt for treatment of TRD patients.

Ejemplares similares